John T. Anderson

发表

Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study

I. Pavord, D. Shaw, B. Hargadon, 2014, European Respiratory Journal.

Optimal Management of Hereditary Angioedema: Shared Decision-Making

A. Banerji, John T. Anderson, D. Johnston, 2021, Journal of asthma and allergy.

subjects and stable asthma patients Airway contribution to alveolar nitric oxide in healthy

I. Pavord, D. Shaw, A. Malinovschi, 2015 .

Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy

W. Lumry, John T. Anderson, D. Levy, 2021, Allergy, Asthma & Clinical Immunology.

Elevated levels of NO are localized to distal airways in asthma.

N. Fineberg, A. Gaggar, M. Dransfield, 2011, Free radical biology & medicine.

Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hereditary Angioedema.

William H. Yang, J. Bernstein, H. Farkas, 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Subsets of airway myeloid-derived regulatory cells distinguish mild asthma from chronic obstructive pulmonary disease.

A. Gaggar, M. Dransfield, E. Abraham, 2015, The Journal of allergy and clinical immunology.

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema

I. Hussain, M. Cicardi, I. Pragst, 2018, Pediatric allergy, immunology, and pulmonology.

Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema.

John T. Anderson, A. Relan, C. Farrell, 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report

T. Craig, K. Bork, H. Longhurst, 2021, Allergy, Asthma & Clinical Immunology.

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Abstracts from the 10th C1-inhibitor deficiency workshop

William H. Yang, A. Szilágyi, M. Margaglione, 2017, Allergy, Asthma & Clinical Immunology.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

P. Keith, T. Machnig, J. Bernstein, 2018, The journal of allergy and clinical immunology. In practice.

Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.

T. Machnig, J. Bernstein, W. Lumry, 2019, The journal of allergy and clinical immunology. In practice.

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial.

William H. Yang, J. Bernstein, H. Iocca, 2020, The Journal of allergy and clinical immunology.

Risk for Attacks in Hereditary Angioedema (HAE) Population Correlates with C1-inhibitor Functional Activity (C1-INHact)

J. Bernstein, H. Farkas, M. Cicardi, 2017 .

3 Shock Management of Shock

M. Sena, John T. Anderson, J. Holcroft, 2011 .

Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study

N. Patel, D. Vinh, V. Bonagura, 2021, Journal of Clinical Immunology.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

University of Southern Denmark Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hereditary Angioedema

William H. Yang, H. Farkas, I. Pragst, 2020 .